These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2869341)

  • 1. Gynaecomastia after spironolactone and potassium canrenoate.
    Bellati G; Idéo G
    Lancet; 1986 Mar; 1(8481):626. PubMed ID: 2869341
    [No Abstract]   [Full Text] [Related]  

  • 2. Disappearance of spironolactone-induced gynaecomastia during treatment with potassium canrenoate.
    Dupont A
    Lancet; 1985 Sep; 2(8457):731. PubMed ID: 2863716
    [No Abstract]   [Full Text] [Related]  

  • 3. Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long-term K-canrenoate or spironolactone therapy.
    Andriulli A; Arrigoni A; Gindro T; Karbowiak I; Buzzetti G; Armanini D
    Digestion; 1989; 44(3):155-62. PubMed ID: 2697627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Controlled study of the effect of long-term administration of canrenoate potassium in cirrhotic ascites].
    Traina M; Vizzini GB
    Minerva Med; 1986 Jan; 77(3-4):87-91. PubMed ID: 3511409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Sexual side-effects of spironolactones. Possible mechanisms of their anti-androgen action].
    Corvol P; Mahoudeau JA; Valcke JC; Ménard J; Bricaire H
    Nouv Presse Med; 1976 Mar; 5(11):691-4. PubMed ID: 177946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphocyte function tests in cirrhotic patients under treatment with spironolactone and potassium canrenoate.
    Cuppone R; Del Vecchio S; Zanninelli G; Delle Monache M; Ulissi A; Tavanti A; Angeloni A; Ricci GL
    J Int Med Res; 1988; 16(6):436-42. PubMed ID: 3266156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spironolactone metabolism and gynaecomastia.
    Overdiek JW; Merkus FW
    Lancet; 1986 May; 1(8489):1103. PubMed ID: 2871374
    [No Abstract]   [Full Text] [Related]  

  • 8. The use of diuretics in preventing ascites recurrence.
    Arrigoni A; Andriulli A; Gindro T; Verme G
    Br J Clin Pract; 1988 Mar; 42(3):116-20. PubMed ID: 3207572
    [No Abstract]   [Full Text] [Related]  

  • 9. [Effect of spironolactone and K-canrenoate in ascitic cirrhosis. Double-blind study].
    Tempini S; Bellati G; Ideo G
    Minerva Dietol Gastroenterol; 1984; 30(3):255-61. PubMed ID: 6504374
    [No Abstract]   [Full Text] [Related]  

  • 10. Eplerenone relieves spironolactone-induced painful gynaecomastia in patients with decompensated hepatitis B-related cirrhosis.
    Mimidis K; Papadopoulos V; Kartalis G
    Scand J Gastroenterol; 2007 Dec; 42(12):1516-7. PubMed ID: 17907040
    [No Abstract]   [Full Text] [Related]  

  • 11. Spironolactone and potassium canrenoate in normal man.
    Ramsay L; Shelton J; Harrison I; Tidd M; Asbury M
    Clin Pharmacol Ther; 1976 Aug; 20(2):167-77. PubMed ID: 780038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spironolactone and potassium canrenoate metabolism.
    Gardiner P
    Lancet; 1985 Dec 21-28; 2(8469-70):1432. PubMed ID: 2867429
    [No Abstract]   [Full Text] [Related]  

  • 13. Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial.
    Angeli P; Fasolato S; Mazza E; Okolicsanyi L; Maresio G; Velo E; Galioto A; Salinas F; D'Aquino M; Sticca A; Gatta A
    Gut; 2010 Jan; 59(1):98-104. PubMed ID: 19570764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of spironolactone and potassium canrenoate on cytosolic and nuclear androgen and estrogen receptors of rat liver.
    Francavilla A; Di Leo A; Eagon PK; Polimeno L; Guglielmi F; Fanizza G; Barone M; Starzl TE
    Gastroenterology; 1987 Oct; 93(4):681-6. PubMed ID: 3623016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spironolactone and canrenoate-K: relative potency at steady state.
    Ramsay L; Asbury M; Shelton J; Harrison I
    Clin Pharmacol Ther; 1977 May; 21(5):602-9. PubMed ID: 858213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative clinical study of spironolactone and potassium canrenoate. A randomized evaluation with double cross-over.
    Emili M; Cuppone R; Ricci GL
    Arzneimittelforschung; 1988 Oct; 38(10):1492-5. PubMed ID: 3058132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vivo metabolites of spironolactone and potassium canrenoate: determination of potential anti-androgenic activity by a mouse kidney cytosol receptor assay.
    Armanini D; Karbowiak I; Goi A; Mantero F; Funder JW
    Clin Endocrinol (Oxf); 1985 Oct; 23(4):341-7. PubMed ID: 4064345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spironolactone and canrenoate: different antialdosteronic diuretic agents.
    Gentilini P
    Hepatology; 1991 May; 13(5):999-1000. PubMed ID: 2030004
    [No Abstract]   [Full Text] [Related]  

  • 19. Liver: diuretic agents for ascites: joining forces from the start?
    Ginès P
    Nat Rev Gastroenterol Hepatol; 2010 Jun; 7(6):310-1. PubMed ID: 20523351
    [No Abstract]   [Full Text] [Related]  

  • 20. Spironolactone diuresis in patients with cirrhosis and ascites.
    Eggert RC
    Br Med J; 1970 Nov; 4(5732):401-3. PubMed ID: 5481518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.